Recursion Pharmaceuticals' stock has plummeted 57% since February, with significant failures in its lead drug REC-994 and other clinical candidates, raising concerns about its AI-driven drug discovery ...
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
Unele rezultate au fost ascunse, deoarece pot fi inaccesibile pentru dvs.
Afișați rezultatele inaccesibile